Document is current
Any future updates will be listed below
-
Authors
Mikami, Naoaki
Kitakado, Hideaki
Kimura, Naoki
Sakakibara, Nana
Nozu, Kandai
Hamada, Riku https://orcid.org/0000-0002-7151-459X
- License Information
-
More Information
Article History
Received: 6 February 2025
Revised: 26 March 2025
Accepted: 26 March 2025
First Online: 29 April 2025
Declarations
:
: The authors declare that they have obtained written consent from the patient’s parents for the publication of the content of this report and any associated supplementary material.
: Kandai Nozu is a member of an advisory group for Kyowa Kirin Co. Ltd., Toa Eiyo LTD., Zenyaku Kogyo Co. Ltd., and Taisho Pharmaceutical Co. Ltd. and has a patent for developing exon skipping therapy for Alport syndrome. Kandai Nozu has also received lecture fees from Ono Pharma, Astellas Pharma, Novo Nordisk Pharma, Sumitomo Pharma, Sanofi, Otsuka Pharma, Daiichi Sankyo, and Miyarisan and a grant from Zenyaku Kogyo and Torii Co. Ltd. The other authors declare no competing interests.
